EGFR (C797S/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.C797S;p.L858R
Components
p.C797Sp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 97.8% | 2.2% | 96.49 |
| 2 | Neratinib | 97.5% | 2.5% | 93.18 |
| 3 | Erlotinib | 96.8% | 3.2% | 99.75 |
| 4 | Dacomitinib | 96.6% | 3.4% | 97.99 |
| 5 | Afatinib | 95.7% | 4.3% | 98.50 |
| 6 | Vandetanib | 95.5% | 4.5% | 95.74 |
| 7 | Bosutinib | 95.4% | 4.6% | 87.22 |
| 8 | Gefitinib | 95.3% | 4.7% | 99.25 |
| 9 | Fostamatinib | 93.6% | 6.4% | 96.74 |
| 10 | Brigatinib | 92.4% | 7.6% | 82.96 |
| 11 | Dasatinib | 89.8% | 10.2% | 87.97 |
| 12 | Pacritinib | 77.4% | 22.6% | 88.64 |
| 13 | Mobocertinib | 76.9% | 23.1% | 97.22 |
| 14 | Lapatinib | 75.8% | 24.2% | 99.25 |
| 15 | Alectinib | 62.3% | 37.7% | 95.49 |
| 16 | Ponatinib | 55.2% | 44.8% | 78.23 |
| 17 | Gilteritinib | 47.8% | 52.2% | 88.97 |
| 18 | Ceritinib | 39.4% | 60.6% | 95.44 |
| 19 | Defactinib | 36.5% | 63.5% | 92.68 |
| 20 | Tivozanib | 29.9% | 70.1% | 92.42 |
| 21 | Osimertinib | 24.0% | 76.0% | 97.24 |
| 22 | Pirtobrutinib | 19.6% | 80.4% | 99.49 |
| 23 | Pazopanib | 16.5% | 83.5% | 97.49 |
| 24 | Nintedanib | 15.7% | 84.3% | 90.23 |
| 25 | Binimetinib | 15.4% | 84.6% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 97.8% | 98.4% | -0.6% |
| Neratinib | 97.5% | 100.0% | -2.5% |
| Erlotinib | 96.8% | 99.4% | -2.7% |
| Dacomitinib | 96.6% | 99.8% | -3.2% |
| Afatinib | 95.7% | 100.0% | -4.3% |
| Vandetanib | 95.5% | 99.3% | -3.8% |
| Bosutinib | 95.4% | 99.3% | -3.9% |
| Gefitinib | 95.3% | 99.9% | -4.6% |
| Fostamatinib | 93.6% | 97.8% | -4.1% |
| Brigatinib | 92.4% | 98.5% | -6.0% |
| Dasatinib | 89.8% | 97.9% | -8.1% |
| Pacritinib | 77.4% | — | — |
| Mobocertinib | 76.9% | 100.0% | -23.1% |
| Lapatinib | 75.8% | 99.2% | -23.3% |
| Alectinib | 62.3% | — | — |
| Ponatinib | 55.2% | — | — |
| Gilteritinib | 47.8% | 91.0% | -43.2% |
| Ceritinib | 39.4% | — | — |
| Defactinib | 36.5% | 94.6% | -58.1% |
| Tivozanib | 29.9% | — | — |
| Osimertinib | 24.0% | 99.1% | -75.1% |
| Pirtobrutinib | 19.6% | — | — |
| Pazopanib | 16.5% | — | — |
| Nintedanib | 15.7% | — | — |
| Binimetinib | 15.4% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms